DisGeNET is a knowledge management platform that integrates and standardizes the data of genes and mutations related to diseases from multiple sources. It covers entire range of human disease.
Source | Last Updated |
---|---|
DisGeNET | July 29, 2024 |
Disease ID | Disease Name | Gene Symbol | Gene ID ▲ | Gene Name | UniProt ID |
---|---|---|---|---|---|
C0007134 | Renal Cell Carcinoma | ST3GAL2 | 6483 | ST3 beta-galactoside alpha-2,3-sialyltransferase 2 | Q16842 |
C0000889 | Acanthosis Nigricans | ELOVL1 | 64834 | ELOVL fatty acid elongase 1 | Q9BW60 |
C0085636 | Photophobia | ELOVL1 | 64834 | ELOVL fatty acid elongase 1 | Q9BW60 |
C0013238 | Dry Eye Syndromes | ELOVL1 | 64834 | ELOVL fatty acid elongase 1 | Q9BW60 |
C0162309 | Adrenoleukodystrophy | ELOVL1 | 64834 | ELOVL fatty acid elongase 1 | Q9BW60 |
C1527231 | Adrenomyeloneuropathy | ELOVL1 | 64834 | ELOVL fatty acid elongase 1 | Q9BW60 |
C0011603 | Dermatitis | ELOVL1 | 64834 | ELOVL fatty acid elongase 1 | Q9BW60 |
C0027651 | Neoplasms | ELOVL1 | 64834 | ELOVL fatty acid elongase 1 | Q9BW60 |
C0020456 | Hyperglycemia | ELOVL1 | 64834 | ELOVL fatty acid elongase 1 | Q9BW60 |
C0005697 | Neurogenic Urinary Bladder | ELOVL1 | 64834 | ELOVL fatty acid elongase 1 | Q9BW60 |
C0011849 | Diabetes Mellitus | ST3GAL4 | 6484 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | Q11206 |
C0011847 | Diabetes | ST3GAL4 | 6484 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | Q11206 |
C1306459 | Primary malignant neoplasm | ST3GAL4 | 6484 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | Q11206 |
C0020456 | Hyperglycemia | ST3GAL4 | 6484 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | Q11206 |
C0002395 | Alzheimer's Disease | ST3GAL4 | 6484 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | Q11206 |
C0011265 | Presenile dementia | ST3GAL4 | 6484 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | Q11206 |
C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | ST3GAL4 | 6484 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | Q11206 |
C0031117 | Peripheral Neuropathy | ST3GAL4 | 6484 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | Q11206 |
C0524620 | Metabolic Syndrome X | ST3GAL4 | 6484 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | Q11206 |
C0020459 | Hyperinsulinism | ST3GAL4 | 6484 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | Q11206 |
C2239176 | Liver carcinoma | ST3GAL4 | 6484 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | Q11206 |
C0233794 | Memory impairment | ST3GAL4 | 6484 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | Q11206 |
C0086651 | Mucopolysaccharidosis, MPS-IV-A | ST3GAL4 | 6484 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | Q11206 |
C0086132 | Depressive Symptoms | ST3GAL4 | 6484 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | Q11206 |
C0011854 | Diabetes Mellitus, Insulin-Dependent | ST3GAL4 | 6484 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | Q11206 |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
GlyCosmos Portal v4.0.0
Last updated: August 19, 2024